OncoMatch/Colorectal Cancer (CRC)/BRAF
Colorectal Cancer (CRC)BRAF Clinical Trials
BRAF V600E mutations occur in 10–15% of metastatic CRC and are associated with poor prognosis, right-sided tumors, and frequent MSI-H co-occurrence. The encorafenib plus cetuximab combination (with or without binimetinib) is FDA-approved for BRAF V600E-mutant metastatic CRC. Trials investigate triplet combinations with immunotherapy, novel BRAF inhibitors, and strategies for non-V600E BRAF alterations.
Top recruiting BRAF Colorectal Cancer (CRC) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
Assistance Publique - Hôpitaux de Paris
Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy
The Netherlands Cancer Institute
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Cancer Research UK
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Institut de Recherches Internationales Servier
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
More BRAF Colorectal Cancer (CRC) trials
17 international trials (no US sites)
Browse other molecular targets with active Colorectal Cancer (CRC) trials.